Ascendis Pharma A/S Ordinary Share (ASND) Next Earnings Date & Options-Implied ±6.8% Move
Ascendis Pharma A/S Ordinary Share (ASND) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Options-Implied Post-Earnings ±6.8% Bell Curve
Will ASND Beat & Rip or Miss Next Quarter?
Trailing EPS: $7.70 • YoY Revenue Growth: 12.1%
Whale Flow & Momentum Playbook: Trading ASND & AI Leaders Without Chasing Tops
- ✓Exact institutional whale strikes & implied earnings range on ASND this week
- ✓How active traders scale setups using funded prop-firm accounts instead of risking savings
- ✓Free bonus: instant RQD Rating Flip alerts on all tracked momentum leaders
ASND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +12.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ASND today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ASND. Explore sector supply chains on /butterfly.
ASND Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhen is ASND's next earnings date?
Based on SEC filing cadence, Ascendis Pharma A/S Ordinary Share (ASND)'s next quarterly earnings window is estimated around Upcoming Quarter.
How much is ASND stock expected to move on earnings?
Options markets currently imply a ±6.8% post-earnings move for ASND, projecting a trading range between $235.8 and $270.2.